J Vet Sci.  2006 Dec;7(4):355-359. 10.4142/jvs.2006.7.4.355.

In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin

• Kim D
• Kordick D
• Divers T
• Chang YF

• KMID: 1089483
• DOI: http://doi.org/10.4142/jvs.2006.7.4.355

Abstract

Antimicrobial susceptibility testing was conducted with 6 different spirochetal strains (4 strains of Leptospira spp. and 2 strains of Borrelia burgdorferi) against 3 antimicrobial agents, commonly used in equine and bovine practice. The ranges of MIC and MBC of amoxicillin against Leptospira spp. were 0.05 - 6.25 microgram/ml and 6.25 - 25.0 microgram/ml, respectively. And the ranges of minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of amoxicillin against B. burgdorferi were 0.05 - 0.39 microgram/ml and 0.20 - 0.78 microgram/ml, respectively. The ranges of MIC and MBC of enrofloxacin against Leptospira spp. were 0.05 - 0.39 microgram/ml and 0.05 - 0.39 microgram/ml, respectively. Two strains of B. burgdorferi were resistant to enrofloxacin at the highest concentration tested for MBC (> or = 100 microgram/ml). Therefore, the potential role of tilmicosin in the treatment of leptospirosis and borreliosis should be further evaluated in animal models to understand whether the in vivo studies will confirm in vitro results. All spirochetal isolates were inhibited (MIC) and were killed (MBC) by tilmicosin at concentrations below the limit of testing (< or = 0.01 microgram/ml).

Keyword

amoxicillin; antibiotics; Borrelia burgdorferi; enrofloxacin; Leptospira spp.; susceptibility; tilmicosin

MeSH Terms

Amoxicillin/pharmacology
Anti-Bacterial Agents/*pharmacology
Borrelia burgdorferi/*drug effects/growth & development/isolation & purification
Fluoroquinolones/pharmacology
Leptospira/*drug effects/growth & development/isolation & purification
Leptospirosis/*microbiology
Lyme Disease/*microbiology
Macrolides/pharmacology
Microbial Sensitivity Tests
Reproducibility of Results
Tylosin/analogs & derivatives/pharmacology

Reference

1. Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc. 2000. 216:371–375.

2. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother. 1992. 36:1788–1790.

3. Alt DP, Zuerner RL, Bolin CA. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar hardjo. J Am Vet Med Assoc. 2001. 219:636–639.

4. Appel MJ, Allan S, Jacobson RH, Lauderdale TL, Chang YF, Shin SJ, Thomford JW, Todhunter RJ, Summers BA. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993. 167:651–664.

5. Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med. 1984. 57:521–525.

6. Chang YF, Ku YW, Chang CF, Chang CD, McDonough SP, Divers T, Pough M, Torres A. Antibiotic treatment of experimentally Borrelia burgdorferi-infected ponies. Vet Microbiol. 2005. 107:285–294.

7. Chang YF, Novosel V, Chang CF, Summers BA, Ma DP, Chiang YW, Acree WM, Chu HJ, Shin S, Lein DH. Experimental induction of chronic borreliosis in adult dogs exposed to Borrelia burgdorferi-infected ticks and treated with dexamethasone. Am J Vet Res. 2001. 62:1104–1112.

8. Chang YF, Novosol V, McDonough SP, Chang CF, Jacobson RH, Divers T, Quimby FW, Shin S, Lein DH. Experimental infection of ponies with Borrelia burgdorferi by exposure to Ixodid ticks. Vet Pathol. 2000. 37:68–76.

9. Dever LL, Jorgensen JH, Barbour AG. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol. 1992. 30:2692–2697.

10. Divers TJ. Robinson NE, editor. Lyme disease. Current Therapy in Equine Medicine. 2003. 5th ed. Saunders;54–56.

11. Donta ST. Macrolide therapy of chronic Lyme Disease. Med Sci Monit. 2003. 9:PI 136–PI 142.

12. Edwards CN, Nicholson GD, Hassell TA, Everard CO, Callender J. Penicillin therapy in icteric leptospirosis. Am J Trop Med Hyg. 1988. 39:388–390.

13. Ellinghausen HC Jr, McCullough WG. Nutrition of Leptospira pomona and growth of 13 other serotypes: fractionation of oleic albumin complex and a medium of bovine albumin and polysorbate 80. Am J Vet Res. 1965. 26:45–51.

14. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sorensen L, Olsson E, Asbrink E. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol. 1992. 72:297–300.

15. Hartmann K, Greene CE. Ettinger SJ, Feldman EC, editors. Diseases caused by systemic bacterial infections. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. 2005. 6th ed. St. Louis: Elsevier Saunders;616–631.

16. Laven R, Andrews AH. Long-acting antibiotic formulations in the treatment of calf pneumonia: a comparative study of tilmicosin and oxytetracycline. Vet Rec. 1991. 129:109–111.

17. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001. 14:296–326.

18. Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother. 1993. 37:1444–1446.

19. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996. 124:785–791.

20. Main BW, Means JR, Rinkema LE, Smith WC, Sarazan RD. Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. J Vet Pharmacol Ther. 1996. 19:225–232.

21. McClain JB, Ballou WR, Harrison SM, Steinweg DL. Doxycycline therapy for leptospirosis. Ann Intern Med. 1984. 100:696–698.

22. Modric S, Webb AI, Derendorf H. Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther. 1998. 21:444–452.

23. Morck DW, Merrill JK, Gard MS, Olson ME, Nation PN. Treatment of experimentally induced pneumonic pasteurellosis of young calves with tilmicosin. Can J Vet Res. 1997. 61:187–192.

24. Murray CK, Hospenthal DR. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob Agents Chemother. 2004. 48:1548–1552.

25. Shryock TR, Apley M, Jones RN, Lein DH, Thornsberry C, Walker JL, White DG, Wu CC. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; approved standard, M31- A2. Vol. 22. pp. 1-80. 2002. Wayne: National Committee for Clinical Laboratory Standards.

26. Oie S, Hironaga K, Koshiro A, Konishi H, Yoshii Z. In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents. Antimicrob Agents Chemother. 1983. 24:905–908.

27. Oschmann P, Kaiser R. Oschmann P, Karaiczy P, Halperin J, Brade V, editors. Therapy and prognosis. Lyme Borreliosis and Tick-borne Encephalitis. 1999. Breman: UNIMed Verlag AG;112–119.

28. Ose EE. In vitro antibacterial properties of EL-870: a new semi-synthetic macrolide antibiotic. J Antibiot (Tokyo). 1987. 40:190–194.

29. Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis. 2003. 36:1507–1513.

30. Scorneaux B, Shryock TR. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. J Dairy Sci. 1999. 82:1202–1212.

31. Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol. 2003. 41:1791–1793.

32. Smith CR, Corney BG, McGowan MR, McClintock CS, Ward W, Ketterer PJ. Amoxycillin as an alternative to dihydrostreptomycin sulphate for treating cattle infected with Leptospira borgpetersenii serovar hardjo. Aust Vet J. 1997. 75:818–821.

33. Straubinger RK, Summers BA, Chang YF, Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol. 1997. 35:111–116.

34. Takashima I, Ngoma M, Hashimoto N. Antimicrobial effects of a new carboxyquinolone drug, Q-35: on five serogroups of Leptospira interrogans. Antimicrob Agents Chemother. 1993. 37:901–902.

35. Tayor SM. Nelson RW, Couto CG, editors. Joint disorders. Small Animal Internal Medicine. 2003. 3rd ed. St. Louis: Mosby;1079–1092.

36. Ward MP, Glickman LT, Guptill LE. Prevalence of and risk factors for leptospirosis among dogs in the United States and Canada: 677 cases (1970-1998). J Am Vet Med Assoc. 2002. 220:53–58.

37. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis. 2000. 31:Suppl 1. 1–14.

38. Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995. 18:340–345.